Decadron “4 mg/1 ml Soluzione iniettabile”

DRUG2 trials

Sponsors

Fondazione IRCCS Istituto Nazionale Dei Tumori, Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.

Conditions

Endometrial cancermetastatic castration resistant prostate cancer (mCRPC)symptomatic bone-only metastatic castration resistant prostate cancer (mCRPC)

Phase 2

Randomized, multicentre phase II trial of the sequencing of Radium-223 and Docetaxel plus prednisone in symptomatic bone-only metastatic castration-resistant prostate cancer (mCRPC)

RecruitingCTIS2024-511660-89-00

Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.metastatic castration resistant prostate cancer (mCRPC), symptomatic bone-only metastatic castration resistant prostate cancer (mCRPC)

Start: 2017-06-09Target: 70Updated: 2025-06-06

Phase 4

Akynzeo as antiemetic treatment in patients with endometrial cancer treated with taxane - platinum combination chemotherapy. NOEME study.

RecruitingCTIS2023-504150-35-00

Fondazione IRCCS Istituto Nazionale Dei TumoriEndometrial cancer

Start: 2024-02-21Target: 84Updated: 2025-12-01